A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

Summary

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a variety of solid tumors, including small cell lung cancer, multiple myeloma, and neuroblastoma, and hematological malignancies.

Timeline

Start

2024-01-24

Primary completion

2027-06-30

Completion

2027-12-31

Drugs

Indications